DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 15.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 4,786 shares of the medical device company’s stock after selling 899 shares during the period. Wilmington Savings Fund Society FSB’s holdings in DexCom were worth $372,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in DexCom by 15.4% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 47,263 shares of the medical device company’s stock valued at $3,676,000 after purchasing an additional 6,290 shares during the period. Consolidated Portfolio Review Corp purchased a new position in shares of DexCom during the 4th quarter valued at approximately $220,000. Mirae Asset Global Investments Co. Ltd. grew its stake in DexCom by 13.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 147,911 shares of the medical device company’s stock valued at $11,768,000 after acquiring an additional 17,650 shares during the period. Stratos Wealth Partners LTD. purchased a new stake in DexCom in the 4th quarter worth $201,000. Finally, E. Ohman J or Asset Management AB raised its position in DexCom by 12.1% during the fourth quarter. E. Ohman J or Asset Management AB now owns 17,600 shares of the medical device company’s stock worth $1,369,000 after acquiring an additional 1,900 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on DXCM. Canaccord Genuity Group lifted their target price on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Royal Bank of Canada lowered their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Leerink Partners dropped their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom has an average rating of “Moderate Buy” and an average price target of $98.41.

DexCom Stock Down 2.1 %

Shares of NASDAQ DXCM opened at $86.38 on Wednesday. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a market capitalization of $33.74 billion, a P/E ratio of 51.72, a P/E/G ratio of 2.26 and a beta of 1.14. The company has a 50 day simple moving average of $81.94 and a 200-day simple moving average of $74.97. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,342 shares of company stock valued at $3,628,069 over the last quarter. 0.30% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.